Atlas Trials

Study to Evaluate the Safety and Efficacy of High Dose Intravenous Immune Globulin (IVIG) Plus Standard Medical Treatment (SMT) Versus SMT Alone in Participants in Intensive Care Unit (ICU) With Coronavirus Disease (COVID-19)

Clinical trial NCT04480424 · COMPLETED

Trial details

NCT number
NCT04480424
Sponsor
Grifols Therapeutics LLC
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
COVID-19
Start date
2020-09-17
Primary completion
2021-08-25
Enrollment
100

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.